CurePSP’s Post

Discover proper quality controls in biobanking to ensure your biospecimens are suitable for their intended use. In this short video clip from our free on-demand webinar, Katharina Krohn, Vice President Global Biobanks, helps explain the insights on the future of biobanking. Tailored for researchers looking to revolutionize their approach to human biospecimen collection and analysis, the full webinar is now on-demand. Katharina's comprehensive overview of cutting-edge techniques and technologies in biobanking, emphasizing their critical role in advancing medical research will help you enhance your studies. Be part of the community shaping the future of personalized medicine and beyond. Watch Now ➡️ https://bit.ly/4acAWx1 #Biobanking #Oncology #PersonalizedMedicine

A major milestone for Epitopea - we’re excited to announce the closing of our USD $31 million pre-Series A financing, bringing our total raised to over USD $45 million. This investment, supported by both new and existing investors, accelerates the development of our next-generation, tumor-selective, RNA-based immunotherapies targeting Cryptigen™ antigens. This funding will help drive Epitopea’s accelerated optimization of its off-the-shelf RNA immunotherapies and its transition to a clinical-stage company delivering differentiated immunotherapies focused on enhancing the durability of clinical response for cancer patients. 🔗 Read the Press Release: [ENG] https://lnkd.in/etU9YDA8 [FR] https://lnkd.in/e9xx6ytY Our investors: Investissement Québec, adMare BioInnovations, Jonathan Milner, Advent Life Sciences, CTI Life Sciences Fund, Cambridge Innovation Capital Fonds de solidarité FTQ, Harrington Discovery Institute at University Hospitals , IRICoR, Novateur Ventures Inc. #Biotech #Innovation #Pharma #Research #Cancer

The Purdue Innovates Incubator, with funding from the Trask Innovation fund, is supporting Purdue University researchers bring their innovations from the lab to the marketplace.   $175,000 in total has been awarded to four short-term projects to further develop innovations in cancer therapeutics, cellular manipulation, and superabsorbent materials. Congratulations to Andrea Kasinski, Senay Simsek, Yoon Yeo, and Jesse (Chi) Zhang on receiving the Spring 2024 round of funding!   “These challenges include a technology becoming obsolete or an inventor feeling dispirited because of a lack of progress,” said Matt Dressler, Funds Manager for the Purdue Innovates Incubator. “Trask funding can address those challenges as Purdue faculty develop a discovery into a viable marketplace product. The fund complements several other Purdue Innovates resources provided to university inventors and entrepreneurs.” Full story: https://bit.ly/3YikFE9   The application deadline for the next round of funding is Sept. 27.   Purdue University College of Science | Purdue University College of Pharmacy | Purdue Agriculture | Purdue Institute for Cancer Research | Purdue Institute for Drug Discovery | Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D) #Purdue #PurdueInnovates #Funding #Cancer #Cells #Materials

🚀 Exciting news from Degrome Therapeutics! They have been awarded $499,883 by the U.S. Department of Health and Human Services (HHS)  , specifically the The National Institutes of Health and the NIH National Institute on Aging. This funding will support their groundbreaking work in developing small-molecule degraders of APP as novel therapeutics for Alzheimer's disease. 🧠 Their innovative approach aims to reduce amyloid production and extracellular deposition, which are key factors in the progression of Alzheimer's. By optimizing APP degrader compounds, they hope to identify lead compounds with improved potency, solubility, and blood-brain barrier permeability. This could be a game-changer in Alzheimer's therapy! 🌟 This award is part of the Small Technology Transfer Research Program Phase I and will last for 12 months, starting on September 1, 2024, and ending on August 31, 2025. Congratulations to Degrome Therapeutics on this significant achievement! #SBIR #STTR #AlzheimersResearch #InnovativeTherapies

✨ Excited to share some great news! ✨ I had the opportunity to present my work at the Faculty & Staff retreat of the Swiss Cancer Research Center Léman (SCCL), alongside many incredible presentations. 🎤🔬 My presentation centered on the mechanism of action of a withanolide derivative in multiple myeloma. The discussions that followed during the coffee break were truly inspiring, with valuable insights from colleagues and leading experts in the field. I want to extend my gratitude to the organizers for giving me this opportunity and to everyone who contributed to making this event so enriching. 💡🤝 If you're interested in discussing this research further or learning more about my work, please don't hesitate to reach out! #CancerResearch #PharmaceuticalSciences #Pharmacognosy

🚀 Exciting Update Alert! 🌟The European Patent Office has highlighted the top innovators in cancer research across Europe! We're all about staying in the know, especially when it comes to game-changing strides in fighting cancer. And guess what? As per the European Patent Office's latest report, three countries are leading the charge: 🥇 Germany 🥈 United Kingdom 🥉 France 📈 This study offers valuable insights into the technology landscape and recent innovation trends in cancer combat. Utilizing global patent data, it presents a comprehensive analysis of cancer-related patents, covering various technologies crucial for diagnosis, prevention, treatment, and potential cure. 💡 Explore how patents play a pivotal role in shaping the future of healthcare. Contact us today to assist you in studying your patents and navigating the world of intellectual property! ☎️: 05 20 30 55 50 📧: contact@ipafrica.net 🌍: https://zurl.co/2B0a 🔗 Link for the full study : https://zurl.co/GshB #CancerInnovation #Europe #Healthcare #IPAFRICA #IPP #EuropeanPatentOffice #Science #Technology #IPCase #IntellectualProperty # #Conseillerenproprieteindustrielle #Germany #UK #France #Brevet #BrevetPharmaceutique

📢 Are you attending the #BiomarkersUK 2024 conference in London? Biognosys will also be there from February 29th to March 1st. Reach out to our team at booth #27 to explore how our #TrueDiscovery®, #TrueSignature®, and #TrueTarget® platforms can help you gain deep biological insights from early discovery and clinical research to #DrugDevelopment. 🧪👥 Attend our talk on March 1st, 12:50 PM, to learn more about "Utilizing unbiased and targeted #Proteomics for #Biomarker discovery." 🧬 #MassSpectrometry #DrugDiscovery #Oncology

Introducing Compare Biomarket: The Ultimate Human Specimens Comparison Tool At the heart of groundbreaking scientific research lies the power of choice. Your choice in human tissues and specimens is your unique Biomarket, a carefully curated selection of providers that resonate with your research needs and goals. We understand this, and our mission is to amplify your power of choice with our innovative Compare Biomarket® platform. We invite you to explore, compare, and discover how your preferred selection of human specimen providers can be complemented by our clinical bio marketplace. Here's what the Compare Biomarket platform offers: ·        Transparent comparisons of healthy and disease-state tissues, biological samples, and pricing to ensure you make the most informed decisions. ·        Assurance of quality and value, with a focus on ethical sourcing and compliance. ·        A streamlined process designed to maximize the efficiency of your research budget and time. Discover the power of easy comparison and informed decision-making. Visit our website today to Compare Your Biomarket and maximize the value of your research budget: www.comparebiomarket.com #liquidbiopsy #diagnostics #biomarkers #cancerresearch #drugdiscovery

🚀 Exciting news from Jillion Therapeutics! They have been awarded $496,373 by the U.S. Department of Health and Human Services (HHS)  , specifically the National Institutes of Health and the NIH National Institute on Aging. This funding will support their groundbreaking research on targeting biologically relevant tau monomers and oligomers using a novel DNA-encoded library (DEL) drug discovery platform to treat Alzheimer's disease and tauopathies. #SBIR #STTR #Innovation 🔬 This Phase I SBIR project aims to identify small molecular weight compounds that can bind to tau protein and modify its biology, ultimately reducing its toxicity. The research will focus on overcoming current limitations in tau drug discovery by using a DEL screening approach, which allows for high-throughput screening with minimal protein usage. The project will last for 12 months, starting on September 1, 2024, and ending on August 31, 2025. #Healthcare #Research #Alzheimers

Thrilled to announce the publication of our new paper 🎊 "Bioinformatic Analysis Reveals Bone Marrow Kinase as a Potential Diagnostic and Prognostic Biomarker for Multiple Cancer Types" in Cureus Journal of Medical Science Grateful for the support of my colleagues Ethar Ahmed, Rihab Ahmed Hassan, Lubna Sulayman Elnour, Amna Makawi, Amna Balla Mohamed Abdalla, Aml Karar Mohamed, and mentors throughout this process. Many thanks to our leader and supervisor Mohamed Alfaki, for his guidance and abundance of information. Read more here: https://lnkd.in/gp63tTYB #academia #research #Bioinformatics.